Stock of Radient Pharmaceuticals Corporation (RXPC) has been in “free-fall” mode for months. On Friday’s trading session RXPC markers showed up a premature uptrend signal.
We’d like to put on scale of your justice just some DO’s and DO NOT’s about Radient. If you feel that DO’s are prevalent than simply join us on RXPC’s adventure.
Start by browsing the following info:
Radient Pharmaceuticals Corporation
2492 Walnut Ave., Suite 100
Tustin, CA. 92780-6953
Tel: (714) 505-4461
Fax: (714) 505-4464
Speech from Mr. Douglas C. MacLellan, Radient’s Chairman & CEO:
Radient Pharmaceuticals Corporation is a Company operating with a single mission: To develop and deliver unique, high-value cancer diagnostic tests that really matter. products for the people we serve—and that commitment is the very essence of who we are.
Superior health is the ultimate priority in life shared by everyone and we at Radient Pharmaceuticals are making this a reality for people across the globe and the critical nature of our IVD cancer tests to millions of people around the world is indisputable. Highlighted by our easy-to-use and potentially life-saving Onko-Sure™ IVD cancer test, we are helping physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis and diagnosis. Our Onko-Sure™ IVD cancer test is used to guide decisions regarding patient treatment, which can include decisions to refer patients to specialists, perform additional testing or assist in the selection of cancer therapy. These are the ways we are paving the way to a healthier, happier, and longer tomorrow for the patients we serve.
We are also steadfast on building an industry-leading, profitable, and growth-oriented Company. Radient Pharmaceuticals is well-positioned for today’s – and tomorrow’s– changing world. We have an exceptionally tenured team; strong product portfolio in segments with significant market demand; and a solid business strategy to meet that demand. Given this, Radient Pharmaceuticals is prepared to achieve the goals we’ve set forth ? goals we believe will deliver solid positive returns for our employees, customers, partners and shareholders.
I’m confident in our focus, brand, business and strategy; our market opportunity and my team’s ability to perform. This is sure to be an exciting journey and I look forward to sharing our achievements and future with you on the road ahead. Thank you in advance for your interest in Radient Pharmaceuticals.
On August 23rd Radient Pharmaceuticals announced that it has sold and shipped its first order of Onko-Sure® test kits to a distributor in Brazil. This initial shipment of kits will be used by the in-country distributor for regulatory approval and clinical validation of the test in Brazilian labs. Prior to the shipment of these test kits, Radient filed for patent protection for Onko-Sure® in Brazil.
On September 14th Company announced that it has filed for patent protection for its proprietary Onko-Sure® cancer test in Australia and New Zealand.
On September 26th Radient announced that it has signed a Regional Distributor Partner Agreement with Irvine-based TS Pharm, Inc. for marketing and distribution of Radient’s Onko-Sure® in Central American and Caribbean nations including: Antigua, Aruba, Bahamas, Barbados, Belize, Bermuda, Cayman Islands, Costa Rica, Curacao, Netherland Antilles, Dominican Republic, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Panama, and Trinidad & Tobago.
For over 10 years, TS Pharm Inc. has been helping place drugs in the Caribbean Islands and in Central American countries. TS Pharm Inc. has recently started distributing pharmaceuticals in the Middle East. At TS Pharm Inc. we thoroughly understand the different countries registration and distribution process, we can easily get reputable Manufacturers and well known Distributors working together to get people the products they need.
RPC’s Business Metrics
Cash on hand: $720,000*
Shares Outstanding: 198 million*
750 million shares to be fully authorized.
Outstanding Warrants & Options: 111 million*
*Approximate number as of August 19, 2011
RPC’s Business Metrics
Cash on hand: $415,000**
Shares Outstanding: 547 million**
750 million shares authorized.
Outstanding Warrants & Options: 111 million*
*Approximate number as of September 23, 2011
Your move… Read some background information on RXPC’s executives, maybe it’ll be helpful in your decision…
Mr. Douglas C. MacLellan
Chairman & Chief Executive Officer
Douglas C. MacLellan is Chairman of the Board of Directors and Chief Executive Officer of Radient Pharmaceuticals Corporation—a US-based pharmaceutical company with major operations in China. Through MacLellan’s leadership, Radient Pharmaceuticals is on an aggressive growth trajectory as an emerging international pharmaceutical company that offers a strong portfolio of in vitro diagnostic cancer tests and high-end skin care products.
With more than 25 years of international business management and active board experience, Mr. MacLellan has been a catalyst for the development, growth and success of many public and privately-held businesses worldwide. Throughout his professional career, Mr. MacLellan has served on the board of 18 separate companies where he has played an instrumental role in strategic planning, general operations, corporate finance activities, economic policy, asset allocation and mergers & acquisitions. In addition, he has supported the raise of over US$715 million in capital financing for development early-stage, start-up and mid-cap companies. Mr. MacLellan has extensive business experience in the People’s Republic of China, and is recognized as an authority on the China government, regulatory, and compliance system; Chinese joint venture; and wholly foreign-owned enterprise (WFOE) structuring.
Companies Mr. MacLellan has served in leadership roles with include MacLellan Group, Inc., a privately held business incubator and financial advisory firm Mr. MacLellan founded in 1992; Board member of Edgewater Foods, International, Inc.; Vice-Chairman of the Board of AXM Pharma, Inc. (AMEX: AXJ), a China based bio-pharmaceutical company; as Vice Chairman of the Board Asia American Telecommunications (now Metromedia China Corporation), a majority owned subsidiary of Metromedia International Group, Inc.; Co-Chairman and Investment Committee member the Strategic East European Fund; President, Chief Executive Officer and Director, PortaCom Wireless, Inc., a company engaged as a developer and operator of cellular and wireless telecommunications ventures in selected developing world markets; Board member and co-founder, FirstCom Corporation, an international telecommunications company that operates an access fiber and satellite network in Latin America (now AT&T Latin America); and, Principal and co-founder of Maroon Bells Capital Partners, Inc., U.S. based merchant bank specializing corporate finance services for international and domestic telecommunications and media companies.
MacLellan received advanced training in classical economic theory and international relations from the University of Southern California and was a student of Arthur Laffer, Ph.D., who later employed him as an economist. Mr. MacLellan has also authored numerous industry-specific research papers and portfolio strategy and economic forecasts over the past 25 years.
Mr. Akio Ariura
Chief Financial Officer & Chief Operating Officer
Mr. Akio Ariura was named Chief Operating Officer of Radient Pharmaceuticals in 2008 and continues to serve in the role of Chief Financial Officer, a senior role Mr. Ariura has held with the Company since. His experience spans over 30 years in both private and publicly-held companies across various industries. As CFO & COO of Radient Pharmaceuticals, Mr. Ariura has worldwide responsibility for Radient’s business operations and finances, including special projects such as Sarbanes-Oxley Compliance, U.S. Securities & Exchange Commission filings, and project management of mergers and acquisitions.
Prior to joining Radient Pharmaceuticals, Mr. Ariura was Vice President, Sunvest Industries, LLC, in Lake Forest, California, where he oversaw the review, development and implementation of yearly budgets and developed internal controls for the company’s operating manufacturing entities. Mr. Ariura also served as Chief Financial Officer for United States operations for Derlan Industries, Inc., Toronto, a Canadian manufacturer with subsidiaries in the U.S. Mr. Ariura holds a B.S. degree in Business Administration from the University of Southern California
Director, Business Development & Investor Relations
Ms. Mir has been an investor relations professional for 13 years, a founder of successful start-up companies, as well as having engaged in technology transfer in both the healthcare and high-tech fields. As an executive at Los Angeles and New York based investor relations agencies, she has advised and represented dozens of publicly traded technology and healthcare companies. Healthcare clients have included leaders in their product categories, as well as emerging companies subsequently sold to global healthcare giants. As an entrepreneur she is founder of ProteaSure, developer of a proteomic in-vitro diagnostic for endometrial cancer. Prior, she had founded, built and sold Polyglot International, the first privately owned language training firm in Moscow, which served over a dozen Fortune 500 clients. Ms. Mir sold Polyglot to Nord Anglia PLC, a global leader in private education. Ms. Mir received her Bachelor of Science in Finance and Political Science from the University of Massachusetts and her M.B.A. from Babson College in Wellesley, Massachusetts.
Dr. Afsaneh Motamed-Khorasani
Director of Oncology
As Director of Oncology. Dr. Motamed-Khorasani is responsible for medical affairs for Radient’s Onko-Sure® in vitro diagnostic (IVD) cancer test, including product research and development, collaboration with Mayo Clinic to advance development of Radient’s next-generation Onko-Sure® IVD cancer test, on-going clinical trial work, authorship and publication of scientific white papers, articles, abstracts and peer-reviewed papers related to Onko-Sure® and future developed products and representation for Radient at various oncology, medical and financial conferences, tradeshows and events.
Dr. Motamed-Khorasani has a tenured and diverse range of experience in medical communication/affairs, basic and industrial research and development, clinical trials and intellectual property. Prior to joining RPC, Dr. Motamed-Khorasani served as a senior scientist and senior medical analyst at Amgen Inc., Microbix Biosystems Inc., Samuel Lunenfeld Research Institute at Mount Sinai Hospital, Princess Margaret Hospital and Vancouver General Hospital. She has more than 15 years experience and national certificates in GLP, GMP, ICH-GCP and FDA regulatory compliance for clinical trials and is a member of professional associations that include the Endocrine Society, American Association of Cancer Research (AACR), Iranian-American Medical Association (IAMA), Bitech and Pharma Professionals Network (BPPN), American Medical Writers Association (AMWA) and Intellectual Property Institute of Canada (IPIC). Dr. Motamed-Khorasani’s research has focused on high throughput approaches in the context of cancer informatics with a particular interest in the use of comparative analysis for the mining of integrated oncology datasets that include protein-protein interaction and gene expression profiling. She has published and presented more than 35 peer-reviewed papers, abstracts, and articles in highly regarded scientific journals, and presented at many high profile conferences and scientific meetings. Of particular note, Dr. Motamed-Khorasani has offered significant contribution in the field of ovarian cancer when she highlighted two genes that may be involved in the prognosis of ovarian cancer. The results of this finding are published in the 2006 edition of the Oncogene Scientific Journal. Dr. Motamed-Khorasani received her PhD degree in Reproductive Endocrinology with a focus on epithelial ovarian cancer from the University of Toronto, Canada.
Mr. Christopher Gee
Director of International Sales & Marketing
Mr. Chris Gee is a technology and biotech industry veteran with extensive international sales, marketing, and distribution management experience. Since 2004 he has held executive positions and managed projects in the USA, PRC China, Hong Kong, and Taiwan including product development, marketing, sales and distribution partnership planning. His oversight spanned US and Asian business operations and included negotiated agreements with top tier distribution companies in Asia. Mr. Gee’s background includes three years as a senior analyst at New York University, Stern School of Business. He has also served as principal in various of start-up companies. While at Apple Inc., he successfully managed business development and enterprise computing projects. Mr. Gee obtained his Masters degree from King’s College, University of London and his Bachelors degree from New York University.
Dr. Guang-Yun Song
Senior Scientist & Lab Manager
As Senior Scientist and Lab Manager, Dr. Song is the lead scientist in the development, design and manufacturing of Radient’s IVDs. He works closely with Radient’s R&D, quality control and kit manufacturing staff to ensure product quality. He has extensive experience in animal model tumor models, tumor immunology, cancer immunotherapy, vaccine development and preclinical evaluations. This experience also includes validation of bio-analytical assays, development of diagnostic kits, and monoclonal and polyclonal antibody purification. Prior to joining Radient, he was a Staff Scientist at Beckman Research Institute of the City of Hope National Medical Center. He has also served as Research Scientist and Head of Immunology Group at Curex Technologies, Research Scientist at StressGen Biotechnologies, Corp., and Deputy General Manager at Shenyang Dongyu Biomedical Co. in China. Dr. Song was a Post-Doctoral Fellow as well as Visiting Scholar at Stanford University. He has also served as Post-Doctoral Fellow at University of British Columbia, BC, Canada. Dr. Song has authored 15 articles in peer-reviewed journals and made 10 presentations at scientific conferences. He is a member of the American Association of Cancer Research and the American Association for the Advancement of Science. He received his M.D. from the Department of Medicine, Norman Bethune University of Medical Sciences, Changchun, China and did Post-Doctorals at Stanford University School of Medicine, Palo Alto, California and University of British Columbia, Vancouver.